Related Experiment Video
Updated: Feb 27, 2026
Using a Chemical Biopsy for Graft Quality Assessment
Published on: June 17, 2020
Design and Reporting Quality of Noninferiority Trials in Kidney Transplantation: A Systematic Review
Bree Shi1,2, Jonathan M Bleasel3, Tracey Ying1,2
1Kidney Node, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
Key Points:
Many kidney transplant noninferiority trials used unjustified or overly generous margins, risking adoption of inferior therapies. Inadequate analyses, poor missing data handling, and weak Consolidated Standards of Reporting Trials (CONSORT) adherence limit trial interpretation. Stronger noninferiority trial design and reporting are needed to improve evidence quality in kidney transplantation.
Background:
Noninferiority trials are essential in kidney transplantation, where established standard-of-care treatments make placebo-controlled designs infeasible, and their use is increasing. We aimed to assess the design and reporting quality of noninferiority trials in kidney transplantation, specifically assessing adherence to existing guidelines.
Methods:
We searched medical literature analysis and retrieval system online, Embase, and Cochrane Central Register of Controlled Trials for randomized controlled noninferiority trials in kidney transplantation published up to February 2025. Two investigators reviewed and extracted data. Study quality was assessed regarding design and reporting quality using key noninferiority design criteria and the Consolidated Standards of Reporting Trials 2012 extension, respectively.
Results:
We identified 43 unique trials: 36 (84%) compared a novel immunosuppressive regimen to standard of care and 26 (60%) were industry sponsored. The noninferiority margin (the worst-case loss in efficacy considered clinically acceptable) was not justified in 28 (65%) studies and poorly justified in seven (16%). Of 32 studies with a categorical primary outcome, 30 (94%) assessed absolute risk reduction rather than relative risk. Most studies had high withdrawal and dropout rates, yet 33 (77%) did not specify methods for handling missing data. Intention-to-treat analysis alone was used to determine primary efficacy in 24 (56%) studies. Twelve studies (28%) provided an incorrect conclusion, most claiming equivalence when noninferiority had not been adequately demonstrated. Both design and reporting quality have improved over time ( P = 0.02, P = 0.002, respectively). No association was evident between design or reporting quality and journal impact factor or sponsor type.
Conclusions:
We found major deficiencies in the design, conduct, and reporting of noninferiority trials in kidney transplantation.
Insights
Noninferiority trials in kidney transplantation show significant design and reporting flaws, particularly in margin justification and handling missing data. Despite improvements, major deficiencies persist in conducting and reporting these essential transplant studies.
Area of Science:
- Nephrology
- Transplantation Medicine
- Clinical Trial Design
Background:
- Noninferiority trials are crucial in kidney transplantation due to the infeasibility of placebo controls.
- The use of noninferiority trial designs in this field is increasing.
- Assessing the quality of these trials is vital for reliable evidence generation.
Purpose of the Study:
- To evaluate the design and reporting quality of noninferiority trials in kidney transplantation.
- To assess adherence to established guidelines for noninferiority trial conduct.
- To identify common deficiencies in trial methodology and reporting.
Main Methods:
- Systematic search of MEDLINE, Embase, and CENTRAL for relevant trials up to February 2025.
- Data extraction and quality assessment by two independent investigators.
- Evaluation using key noninferiority design criteria and the CONSORT 2012 extension.
Main Results:
- 43 trials were identified; 84% compared novel immunosuppression to standard of care; 60% were industry-sponsored.
- Noninferiority margin justification was inadequate in 81% of studies.
- Major issues included inappropriate outcome metrics (94% used absolute risk reduction), poor handling of missing data (77%), and incorrect conclusions (28%).
- Both design and reporting quality showed improvement over time (p=0.02, p=0.002).
Conclusions:
- Significant deficiencies exist in the design, conduct, and reporting of noninferiority trials in kidney transplantation.
- These shortcomings impact the reliability of evidence derived from these trials.
- Improvements are needed to enhance the quality and transparency of noninferiority research in this field.
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:26Kidney Transplant II: Surgical Procedure
01:16Kidney Transplant III: Nursing Management
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
01:08Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...